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David Gray,6 Joe Barrett,6 Silke R. Brix,7 Neeraj Dhaun,8  Stephen P. McAdoo,9  Rona M. Smith,5 
Colin C. Geddes,10 David Jayne,5 Raashid Luqmani,11 Alan D. Salama,12 Mark A. Little,2 and Neil Basu,13  
on behalf of the UK and Ireland Vasculitis Rare Disease Group (UKIVAS)
Objective. COVID- 19 is a novel infectious disease with a broad spectrum of clinical severity. Patients with systemic 
vasculitis have an increased risk of serious infections and may be at risk of severe outcomes following COVID- 19. 
We undertook this study to establish the risk factors for severe COVID- 19 outcomes in these patients, including the 
impact of immunosuppressive therapies.
Methods. A multicenter cohort was developed through the participation of centers affiliated with national UK and 
Ireland vasculitis registries. Clinical characteristics and outcomes are described. Logistic regression was used to 
evaluate associations between potential risk factors and a severe COVID- 19 outcome, defined as a requirement for 
advanced oxygen therapy, a requirement for invasive ventilation, or death.
Results. The cohort included 65 patients with systemic vasculitis who developed COVID- 19 (median age 70 
years, 49% women), of whom 25 patients (38%) experienced a severe outcome. Most patients (55 of 65 [85%]) had 
antineutrophil cytoplasmic antibody– associated vasculitis (AAV). Almost all patients required hospitalization (59 of 
65 [91%]), 7 patients (11%) were admitted to intensive care, and 18 patients (28%) died. Background glucocorticoid 
therapy was associated with severe outcomes (adjusted odds ratio [OR] 3.7 [95% confidence interval 1.1– 14.9]; 
P = 0.047), as was comorbid respiratory disease (adjusted OR 7.5 [95% confidence interval 1.9– 38.2]; P = 0.006). 
Vasculitis disease activity and nonglucocorticoid immunosuppressive therapy were not associated with severe 
outcomes.
Conclusion. In patients with systemic vasculitis, glucocorticoid use at presentation and comorbid respiratory 
disease were associated with severe outcomes in COVID- 19. These data can inform clinical decision- making relating 
to the risk of severe COVID- 19 in this vulnerable patient group.
INTRODUCTION
COVID- 19 is a novel, multisystem infectious disease caused 
by SARS– CoV- 2. COVID- 19 is associated with a broad spec-
trum of clinical severity (1), ranging from asymptomatic disease 
to severe respiratory failure and death. In March 2020, the World 
Health Orga nization (WHO) characterized COVID- 19 as a global 
pandemic (2), prompting considerable concerns from health care 
systems worldwide about their resilience to manage this threat. 
Critical care service capacity was, and remains, a global priority.
Systemic vasculitis is a rare, multisystem autoimmune dis-
order. Compared to other rheumatic musculoskeletal diseases, 
it may result in major organ dysfunction and is therefore typi-
cally managed with more potent immunosuppressive therapy and 
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higher doses of glucocorticoids in order to induce and maintain 
disease remission. While this therapeutic approach success-
fully manages vasculitis activity, glucocorticoid exposure contrib-
utes, in part, to the increased risk of infection in these patients 
(3,4). Thus, although risk factors associated with poor outcomes 
from COVID- 19 in this population are unknown, there is an 
assumption that these patients are at a high risk.
The RECOVERY trial has demonstrated a benefit of moderate- 
dose glucocorticoids in hospitalized general population patients 
with COVID- 19 who require supplemental oxygen or mechanical 
ventilation, but showed potential harm when used in milder disease 
(5). Given these paradoxical effects, it is unknown whether chronic 
background glucocorticoid exposure makes patients more suscep-
tible to severe COVID- 19 infection or whether it might be protective.
We report the results of a coordinated binational effort to 
identify the predictors of a severe outcome in the largest reported 
cohort of systemic vasculitis patients infected with COVID- 19.
PATIENTS AND METHODS
Study design. A registry- based multicenter cohort was 
designed to facilitate rapid real- world data capture. Centers affil-
iated with the UK and Ireland Vasculitis Registry (UKIVAS; www.
ukivas.org/) and the Irish Rare Kidney Disease Registry (RKD; 
www.tcd.ie/medic ine/thkc/resea rch/rare.php) were invited to con-
tribute. UKIVAS covers 89 sites; RKD covers 8 sites across Ire-
land. Participating centers represent both secondary and tertiary 
centers across the UK and Ireland, resulting in a broad population 
sampling frame. A vasculitis- focused COVID- 19 case report form 
was developed, underpinned by standardized BioPortal ontolo-
gies (e.g., SNOMED CT) (6) and interoperable with other emerging 
data sets, such as the COVID- 19 Global Rheumatology Alliance 
(GRA) (7), thereby facilitating future international data linkage as 
the COVID- 19 pandemic progresses. This enables compatibility 
of these data with the principles of the global GO- FAIR initiative 
(8). Additional modules of the UKIVAS and RKD web apps were 
developed to support data capture.
Study population. Patients were eligible for case submis-
sion if they had a diagnosis of systemic vasculitis and COVID- 19 
(laboratory, radiologic, or clinical). The diagnosis of vasculitis was 
determined by the local specialist clinician, according to the Inter-
national Chapel Hill Consensus Conference nomenclature of vas-
culitides (9). Recruitment commenced on March 28, 2020 and is 
ongoing. For this analysis, the final case was submitted on July 
31, 2020. The population sampling frame consisted of individuals 
under the clinical care of sites associated with the UKIVAS and 
RKD registries. At the end of July 2020, there were 795 patients 
in the RKD registry and ~7,400 patients in the UKIVAS registry, 
with 4 patients enrolled in both. In the UK, the Health Research 
Authority decision tool determined that ethics approval was not 
required, and the local sponsor confirmed the project as a service 
evaluation (R&D reference no. GN20RH165). RKD registry ethics 
approval was originally granted by the Tallaght University Hospital/
St. James’s Hospital Joint Research Ethics Committee (reference 
no. 2019- 08 List 29 [07]). All RKD participants provided informed 
consent. Additional approvals were not required.
Study variables. Variables included potential predictors 
of severe outcomes. The selection of predictive variables was 
informed by emerging risk factors for COVID- 19 disease severity 
in other populations (10,11). These included age, sex, ethnicity, 
smoking status, comorbid conditions, immunosuppressive treat-
ment for vasculitis, and vasculitis disease activity. Among the 
comorbid conditions, respiratory disease refers to non– vasculitis- 
related lower respiratory tract disease, though it is possible that 
some patients had coexistent vasculitis- related respiratory dis-
ease. Intravenous immunosuppressive therapy was considered to 
be “current” if the assessing clinician determined that the therapy 
was likely to exert a biologic effect at the time of COVID- 19 diag-
nosis; specific definitions were not provided.
Vasculitis disease activity was determined according to 
global clinician assessment. Outcome data included complica-
tions, such as acute kidney injury (AKI), respiratory failure and 
vasopressor requirement, and death. To enable interoperability, 
the standardized outcomes (grade range 1– 8) from the COVID- 19 
GRA case reporting form were used (see Supplementary Table 1, 
available on the Arthritis & Rheumatology website at http://onlin e  
libr ary.wiley.com/doi/10.1002/art.41728/ abstract) (10). A severe 
outcome was defined as a composite of requirement for advanced 
oxygen therapy (such as noninvasive ventilation or high- flow oxy-
gen device), requirement for invasive ventilation, or death. Dates of 
hospital and intensive care unit (ICU) admission and discharge were 
collected in order to derive length of stay. Other variables were col-
lected to characterize the clinical features of COVID- 19 in patients 
with vasculitis. These included symptoms, laboratory tests, and 
radiology results. Reporting clinicians were asked to indicate which 
of these variables contributed to diagnosis.
Statistical analysis. Continuous variables are described as 
the median and interquartile range (IQR). Categorical variables are 
described as the number and percentage of patients. Associations 
between various explanatory variables and the odds of severe 
outcomes were determined. Unadjusted and age/sex- adjusted 
logistic regression models were individually calculated for each 
explanatory variable and reported as odds ratios (ORs), P values, 
and 95% confidence intervals (95% CIs). The adjusted ORs for 
age and sex were derived from a single logistic regression model 
which included age and sex only. When a potential interaction 
could account for a positive finding, logistic regression model-
ing incorporating the explanatory and interacting variables was 
used. Sensitivity analyses were performed in the event that any 
effects may have been different in an important subgroup. Missing 
data were acknowledged in the relevant tables. P values less than 
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0.05 were considered significant. R (version 4.0.2) was used for 
data analysis with packages including tidyverse and finalfit.
RESULTS
In total, 65 patients with an established diagnosis of sys-
temic vasculitis who developed COVID- 19 were registered. Fifty- 
eight patients were submitted to the UKIVAS registry, and 7 were 
submitted to the RKD registry, with no duplicate submissions.
Baseline characteristics. The median age was 70 years 
(IQR 55– 76 years) and 49% of the patients were female (Table 1). 
The majority of patients (55 of 65 [85%]) had antineutrophil cyto-
plasm antibody– associated vasculitis (AAV): of these, 24 patients 
(44%) had granulomatosis with polyangiitis, 25 patients (45%) 
had microscopic polyangiitis, and 6 patients (11%) had eosino-
philic granulomatosis with polyangiitis. The characteristics of AAV 
patients were broadly similar to those of the full cohort (data not 
shown). Thirty- two patients (49%) were assessed as having con-
current active disease. Fifteen patients (23%) were suspected 
to have contracted COVID- 19 through a health care setting; of 
these, 9 patients (60%) had some degree of active vasculitis. In 
one case, COVID- 19 was considered to have increased disease 
activity. For the remaining patients, COVID- 19 was not perceived 
to have altered or induced disease activity.
Forty- seven patients (72%) were diagnosed by polymerase 
chain reaction (PCR) testing, 3 patients (5%) did not have PCR- 
confirmed disease but had radiologic evidence of disease, and 3 
Table 1. Baseline characteristics of the study patients (n = 65)*
Characteristic Value Characteristic Value
Age, median (IQR) years 70 (55– 76) Vasculitis, active disease 32 (49.2)
Female sex 32 (49.2) Vasculitis disease duration,  
median (IQR) years
2.2 (0.76– 6.8)
Ethnicity Current immunosuppressive therapy
Asian 7 (10.8) Any immunosuppressive therapy 56 (86.2)
Black 1 (1.5) Any immunosuppressive therapy 
and GCs
43 (66.2)
White 46 (70.8) Azathioprine 12 (18.5)
Not stated 6 (9.2) GCs (any dose) 45 (69.2)
Missing data 5 (7.7) Prednisone 1.0– 5.0 mg/day 19 (29.2)
Smoking status Prednisone ≥5.1 mg/day 26 (40.0)
Current 3 (4.6) Unknown/missing data 2 (3.1)
Former 15 (23.1) CYC 10 (15.4)
Never 26 (40.0) HCQ 4 (6.2)
Unknown/missing data 21 (32.3) IVIG 1 (1.5)
Comorbidities MMF 11 (16.9)
Vasculitis† Rituximab 22 (33.8)
GPA (or PR3 AAV) 24 (36.9) Tacrolimus 4 (6.2)
MPA (or MPO AAV) 25 (38.5) Other medications
EGPA 6 (9.2) ACE inhibitors 9 (13.8)
LVV 2 (3.1) ARB 8 (12.3)
Behçet’s disease 1 (1.5) NSAIDs 2 (3.1)
PAN 1 (1.5) Unknown/missing data 5 (7.7)
Other 5 (7.7) Laboratory tests, median (IQR)
Unknown/missing data 1 (1.5) Creatinine, μmoles/liter¶ 127 (69– 204)
Diabetes 13 (20.0) CRP, mg/liter 99 (44– 149)
Hypertension 25 (38.5) Lymphocytes, ×109/liter 0.7 (0.4– 0.9)
CVD 17 (26.2) Method used for COVID- 19 diagnosis
Respiratory disease‡ 13 (20.0) PCR 47 (72.3)
Renal disease 30 (46.2) Radiologic 3 (4.6)
End- stage kidney disease§ Symptoms only 3 (4.6)
Yes 17 (26.2) Unknown/missing data 12 (18.5)
No 46 (70.8)
Unknown/missing data 2 (3.1)
Organ transplant 3 (4.6)
* Except where indicated otherwise, values are the number (%) of patients. IQR = interquartile range; GPA = granulomatosis with polyangiitis; 
PR3 = proteinase 3; AAV = antineutrophil cytoplasmic antibody– associated vasculitis; MPA = microscopic polyangiitis; MPO = myeloperoxidase; 
EGPA = eosinophilic granulomatosis with polyangiitis; LVV = large vessel vasculitis; PAN = polyarteritis nodosa; CVD = cardiovascular disease; 
GCs = glucocorticoids; CYC = cyclophosphamide; HCQ = hydroxychloroquine; IVIG = intravenous immunoglobulin; MMF = mycophenolate mofetil; 
ACE = angiotensin- converting enzyme; ARB = angiotensin II receptor blocker; NSAIDs = nonsteroidal antiinflammatory drugs; CRP = C- reactive 
protein; PCR = polymerase chain reaction. 
† Other vasculitis diagnoses include IgA vasculitis, leukocytoclastic vasculitis, and unspecified vasculitis. 
‡ Refers to non– vasculitis- related lower respiratory tract disease, though it is possible that some patients had coexistent vasculitis- related 
respiratory disease. 
§ Includes 13 patients receiving hemodialysis, 3 kidney transplant recipients, and 1 patient with sustained stage 5 chronic kidney disease. 
¶ Excludes patients receiving hemodialysis. 
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patients (5%) were diagnosed by clinical presentation only (Table 1). 
Data on diagnostic testing were unknown/missing for 12 patients 
(19%). The characteristics of those diagnosed by PCR testing 
were broadly similar to the full cohort (data not shown).
Most patients were receiving background glucocorticoids 
(45 of 65 [69%]) at the time of COVID- 19 diagnosis. Nineteen 
patients (29%) were receiving the equivalent of ≤5 mg pred-
nisone, and 26 patients (40%) were receiving >5 mg. For those 
receiving background glucocorticoids, the median dose was the 
equivalent of 7.5 mg prednisone daily (IQR 5– 25 mg). Twenty- 
two patients (34%) and 10 patients (15%) had recently been 
treated with rituximab and cyclophosphamide, respectively 
(Table 1).
Symptom frequency. The most common symptoms 
among the included patients were dyspnea (41 of 65 [63%]), fever 
(38 of 65 [58%]), and cough (37 of 65 [57%]) (Figure 1). Full data 
on symptoms were missing for 2 patients. Hemoptysis occurred 
in 3 patients (5%), and epistaxis occurred in 3 individuals (5%); 
of these, 1 patient had both epistaxis and hemoptysis. Of note, 
some of these patients had ongoing disease activity prior to COV-
ID- 19 diagnosis.
Complication frequency. Respiratory failure was the most 
commonly reported complication among patients (35 of 65 [54%]), 
followed by AKI (12 of 65 [18%]) and secondary infection (10 of 
65 [15%]) (Figure 2). Full data on complications were missing for 
10 patients.
Clinical outcomes. Almost all patients required hospital-
ization (59 of 65 [91%]); 7 patients (11%) were admitted to an 
ICU, and 18 patients (28%) died (Table 2). The median length 
of hospital stay for discharged patients was 11 days (IQR 5– 27 
days). A severe outcome was experienced by 25 of 65 patients 
(38%).
Predictors of severe outcomes. Patients with comorbid 
respiratory disease were more likely to experience a severe out-
come than those without (adjusted OR 7.5 [95% CI 1.9– 38.2]; 
P = 0.006), as were those who had been receiving glucocorticoids 
(adjusted OR 3.7 [95% CI 1.1– 14.9]; P = 0.047) (Table 3). Glu-
cocorticoid exposure remained a poor prognostic indicator even 
after adjusting for vasculitis disease activity (data not shown). A 
sensitivity analysis including only patients with a confirmed PCR 
diagnosis (n = 47) was performed, which demonstrated effect 
sizes consistent with these findings; this was statistically sig-
nificant for comorbid respiratory disease but not for glucocorti-
coid exposure (data not shown). A sensitivity analysis was also 
performed for individuals with AAV (n = 55) with a similar result. 
There was insufficient power to assess the association between 
glucocorticoid dose and poor outcome. Similarly, there was insuf-
ficient power to assess for differences between common nonglu-
cocorticoid immunosuppressive agents. Associations were not 
demonstrated for any demographics, other comorbid conditions, 
vasculitis diagnosis, vasculitis disease activity, or nonglucocorti-
coid immunosuppressant medication.
DISCUSSION
This multicenter study includes the largest cohort of patients 
with systemic vasculitis who have developed COVID- 19 to date. 
It identifies comorbid respiratory disease and background gluco-
corticoid therapy as significant predictors of a severe outcome, 
defined as a need for advanced oxygen therapy or invasive ven-
tilation, or death. Routinely used nonglucocorticoid immunosup-
pressants, such as rituximab and cyclophosphamide, were not 
associated with a severe outcome, nor was vasculitis disease 
activity.
Glucocorticoids have pleotropic immunologic effects and are 
generally considered risk factors for infections (12). Glucocorti-
coids at high doses have been associated with prolonged viral 
shedding, with a similar effect being observed in other corona-
viruses (13,14). That glucocorticoids are associated with worse 
COVID- 19 disease outcomes is consistent with findings from 
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across the rheumatic autoimmune spectrum, as demonstrated by 
the COVID- 19 GRA study (10). Our point estimate for the asso-
ciation of any glucocorticoid dose with severe outcomes (OR 3.7 
[95% CI 1.09– 14.9]) was comparable to that of the COVID- 19 
GRA evaluation of steroids equivalent to ≥10 mg prednisone per 
day (OR 2.05 [95% CI 1.06– 3.96). The confidence interval for this 
finding is relatively wide, and thus, it remains to be determined if 
there is a dose threshold at which risk commences.
The association between glucocorticoids and severe out-
comes may appear to conflict with findings from the RECOVERY 
trial (5). This trial demonstrated that low- dose dexamethasone had 
a substantial survival benefit in patients hospitalized with  COVID- 19. 
However, the groups that benefited in RECOVERY were those 
requiring supplemental oxygen, with the greatest benefit derived 
in those requiring mechanical ventilation. In fact, the point estimate 
for patients not requiring oxygen suggested that glucocorticoids 
could be associated with increased mortality, though this was not 
a statistically significant finding (5). Therefore, prior to requiring oxy-
gen, it may be that glucocorticoids are deleterious, as observed in 
this and other studies of autoimmune disease (15). Our finding that 
comorbid respiratory disease (most commonly chronic obstruc-
tive pulmonary disease, asthma, and interstitial lung disease) was 
associated with severe disease outcomes was consistent with 
a recent general population meta- analysis (16). Among some 





Unknown/missing data 9 (13.8)
Graded outcome (grade no.)
Not hospitalized, no limitations on activities (1) 2 (3.1)
Not hospitalized, limitation on activities (2) 3 (4.6)
Hospitalized, not requiring supplemental oxygen (3) 9 (13.8)
Hospitalized, requiring supplemental oxygen (4) 25 (38.5)
Hospitalized, on noninvasive ventilation or high- flow 
oxygen devices (5)
4 (6.2)
Hospitalized, on invasive mechanical ventilation or ECMO (6) 3 (4.6)
Death (7) 18 (27.7)
Unknown/missing data (8) 1 (1.5)
Length of hospital stay, median (IQR) days 11 (5– 27)
Length of hospital stay, unknown/missing data 40 (61.5)
* Except where indicated otherwise, values are the number (%) of 
patients. ICU = intensive care unit; ECMO = extracorporeal membrane 
oxygenation. 
Table 3. Unadjusted and adjusted ORs for potential risk factors and association with severe outcomes*
No. of severe 
outcomes/  





Female 13/26 (50) 1.04 (0.51– 2.10) 1.05 (0.52– 2.13)
Age – 1.01 (0.98– 1.05) 1.01 (0.98– 1.05)
Vasculitis diagnosis
GPA (referent: not GPA) 12/24 (50) 1.71 (0.62– 4.81) 2.19 (0.68– 7.63)
MPA (referent: not MPA) 7/25 (28) 0.53 (0.17– 1.52) 0.43 (0.13– 1.36)
Comorbidities (referent: individual comorbidity 
not present)
Hypertension 12/25 (48) 1.46 (0.71– 3.04) 1.39 (0.64– 3.04)
CVD 8/17 (47) 1.32 (0.59– 2.93) 1.08 (0.52– 2.23)
Respiratory disease 10/13 (77) 7.50 (1.99– 36.94) 7.53 (1.93– 38.22)†
Diabetes 6/13 (46) 1.25 (0.51– 2.99) 1.20 (0.48– 2.92)
Renal disease 12/30 (40) 1.00 (0.49– 2.03) 1.05 (0.52– 2.14)
End- stage kidney disease 6/17 (35) 0.85 (0.25– 2.65) 0.77 (0.22– 2.48)
Smoking status
Ever smoker (referent: never) 9/18 (50) 2.25 (0.65– 8.05) 2.33 (0.62– 9.28)
Immunosuppressive therapy
Any immunosuppressive therapy (referent: not 
receiving immunosuppressive therapy)
24/55 (44) 3.10 (0.70– 21.79) 3.66 (0.77– 27.29)
GCs (referent: no prednisone)
Prednisone (any dose) 22/45 (49) 3.35 (1.02– 13.2) 3.66 (1.09– 14.9)‡
Prednisone 1.0– 5.0 mg/day 10/19 (53) 3.89 (0.98– 17.93) 3.76 (0.91– 18.02)
Prednisone ≥5.1 mg/day 12/26 (46) 3.00 (0.82– 12.86) 3.32 (0.86– 15.35)
Other immunosuppressive therapy
Azathioprine (referent: not receiving azathioprine) 6/12 (50) 1.65 (0.46– 5.97) 1.57 (0.42– 5.85)
CYC (referent: not receiving CYC) 5/10 (50) 1.62 (0.41– 6.48) 1.83 (0.44– 7.76)
Rituximab (referent: not receiving rituximab) 9/22 (41) 1.06 (0.36– 3.01) 1.25 (0.40– 3.90)
* A severe outcome was defined as a composite of requirement for advanced oxygen therapy (such as noninvasive 
ventilation or high- flow oxygen device), requirement for invasive ventilation, or death. A separate logistic regression 
model including sex and age as a continuous variable was calculated for each explanatory variable. The adjusted models 
for age and sex were derived from a single logistic regression model which included sex and age as a continuous variable. 
OR = odds ratio; 95% CI = 95% confidence interval (see Table 1 for other definitions). 
† P < 0.00645. Respiratory disease refers to non– vasculitis- related lower respiratory tract disease, though it is possible 
that some patients had coexistent vasculitis- related respiratory disease. 
‡ P < 0.047. 
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patients with chronic lung disease, enhanced re spiratory tract 
angiotensin- converting enzyme 2 expression, the principal bind-
ing site for COVID- 19 cell entry, is a possible explanation for this 
association (10). Consistent with findings from the COVID- 19 GRA 
study, we did not find an association of adverse disease outcomes 
with other immunosuppressive agents (17). This is reassuring, 
as current guidance emphasizes the importance of maintaining 
immunosuppressive therapy among uninfected patients due to 
concerns of destabilizing disease control (18).
This cohort represents a severely affected group, as reflected 
by the very high proportion of hospitalization (91%). The mortality 
rate of 28% is similar to that reported in the largest UK study of 
hospitalized patients carried out by the International Severe Acute 
Respiratory and emerging Infections Consortium (ISARIC) WHO 
Clinical Characterisation Protocol UK (CCP- UK) group, in which 
26% of patients died (18). Age, sex, and symptom distribution were 
also broadly similar to the ISARIC WHO CCP- UK study. The most 
common symptoms, in that cohort and ours, were those that have 
been the most prominent in the case definition: breathlessness, 
fever, and cough. Both active pulmonary vasculitis and COVID- 19 
are recognized causes of hemoptysis (18,19). In the ISARIC WHO 
CCP- UK group, 3.5% of patients experienced this symptom, com-
pared to 3 patients (4.8%) in our cohort. None were thought to 
have diffuse alveolar hemorrhage, as assessed by the responding 
clinician. Differentiating COVID- 19 from active pulmonary vasculitis 
remains a challenge, and indeed these presentations may coexist. 
Ensuring that these diagnoses are considered when a patient with 
vasculitis presents with hemoptysis remains of high importance.
A large proportion of patients (49%) had concurrent active vas-
culitis. A considerable proportion of these patients were believed to 
have contracted COVID- 19 from a health care setting. Notably, the 
onset of vasculitis disease activity preceded COVID- 19 infection in 
almost all cases. However, it is unknown whether COVID- 19 may 
trigger vasculitis activity in the longer term. The emergence of pedi-
atric multisystem inflammatory syndrome temporally associated 
with SARS– CoV- 2, a condition bearing strong similarities to Kawa-
saki disease, is a potential example of SARS– CoV- 2 triggering 
autoimmune vasculitis, though the pathogenesis is not currently 
understood (20). We did not find evidence of vasculitis being trig-
gered in the short term. Longitudinal studies will seek to address 
this question. The prevalence of active disease in this cohort was 
higher than expected— previous cross- sectional UK studies have 
shown disease activity prevalence at ~20% (21). Although disease 
activity was not associated with worse outcomes, it may be that 
patients with unstable disease are more vulnerable to contracting 
COVID- 19. Physician or patient- led reduction in immunosuppres-
sive treatment, in a bid to limit the impact of COVID- 19, is another 
potential reason accounting for a high proportion of disease activ-
ity. Due to the study design, our data are limited in the extent to 
which they can answer this question.
Ascertainment bias is likely to have affected this study. Given 
that most patients were hospitalized, it is likely that patients 
with milder disease were not identified. The number of PCR- 
diagnosed COVID- 19 patients in our study as a proportion of the 
combined UKIVAS and RKD populations was similar to the pro-
portion of UK cases relative to the UK population for a comparable 
time period (22). However, due to the study design, it is not pos-
sible to derive incidence rates. Patients with vasculitis may have 
been more likely to contract COVID- 19 due to risk factors such as 
immunosuppressive therapy and the need to attend health care 
facilities; therefore, ascertainment bias remains possible.
There was a high preponderance of small vessel vasculitis 
(SVV) in this study compared to giant cell arteritis (GCA). Although 
it is a more common condition, patients with GCA are typically 
older and may have adopted stricter self- isolation restrictions 
(according to national guidance). In addition, SVV may have pre-
dominated due to a disproportionate number of renal depart-
ments, compared to rheumatology centers, represented in the 
UKIVAS registry. Due to a large majority of patients in this study 
having SVV, the extent to which its findings can be generalized to 
other vasculitides is limited. Other limitations of this study include 
a relative lack of power. As a result, our analyses may not detect 
some clinically significant effects, and, conversely, the risk of 
spurious findings is higher. Similarly, due to the limited number 
of events, our ability to control for multiple potential confounding 
factors was limited. Due to the heterogeneous immunobiology, 
phenotypes, and management approaches of systemic vasculi-
tis, it is possible that individual disorders may incur different risks; 
due to insufficient power, we were limited in the extent to which 
this could be examined.
This study is the first to describe a cohort of vasculitis patients 
with COVID- 19. The clinical presentation of COVID- 19 was simi-
lar to descriptions in large series of patients without autoimmune 
disease. Glucocorticoids were associated with an increased risk 
of severe outcomes, but other immunosuppressants were not. 
Patients with autoimmune disease have been considered vulnera-
ble during the COVID- 19 pandemic, and many governments have 
instructed that they adhere to exceptional social isolation restric-
tions. While patients with systemic vasculitis remain at a higher risk 
for severe outcomes, these data indicate that some patients may 
not need to face similar restrictions in the future if other known 
risk factors are absent. Conversely, patients who are receiving 
background glucocorticoids or have comorbid respiratory disease 
should be closely monitored when presenting with COVID- 19, 
since their risk of progression to a severe state appears to be 
higher (11). This study primarily describes a cohort of hospitalized 
patients and is thus more likely to reflect severe COVID- 19 dis-
ease. Future work should seek to establish risk factors for severe 
disease in a wider population. Comparisons with controls who did 
not contract COVID- 19 would allow for assessment of incidence 
and risk factors for contracting COVID- 19.
Taken together with findings from other cohorts exposed to 
immunosuppressant medication, these data could inform future 
public health guidance for patients with autoimmune disease. 
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These data were designed to be interoperable with other national 
data sets. Future work should seek to combine international 
efforts to allow for greater power to assess the factors that impact 
this potentially vulnerable group.
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